Healthcare stakeholders are set to adopt a supportive risk posture that integrates low-level red-light therapies and predictive analytics into clinical protocols, bolstered by findings of their low-risk and high-benefit profile. Current research confirms these noninvasive treatments enhance eye, bone, pain, and cognitive functions, while cutting-edge machine-learning models predict myopia progression with high accuracy. This strategic shift aims to standardize guidelines and establish real-world data collection for ongoing assessment, paving the way for broader deployment in clinical practice.